npj Metabolic Health and Disease最新文献

筛选
英文 中文
Periodic dietary restriction of animal products induces metabolic reprogramming in humans with effects on cardiometabolic health. 定期限制动物产品的饮食可诱导人类代谢重编程,对心脏代谢健康产生影响。
npj Metabolic Health and Disease Pub Date : 2025-01-01 Epub Date: 2025-04-09 DOI: 10.1038/s44324-025-00057-2
Konstantinos Rouskas, Ozvan Bocher, Alexandros Simistiras, Christina Emmanouil, Panagiotis Mantas, Anargyros Skoulakis, Young-Chan Park, Alexandros Dimopoulos, Stavros Glentis, Gabi Kastenmüller, Eleftheria Zeggini, Antigone S Dimas
{"title":"Periodic dietary restriction of animal products induces metabolic reprogramming in humans with effects on cardiometabolic health.","authors":"Konstantinos Rouskas, Ozvan Bocher, Alexandros Simistiras, Christina Emmanouil, Panagiotis Mantas, Anargyros Skoulakis, Young-Chan Park, Alexandros Dimopoulos, Stavros Glentis, Gabi Kastenmüller, Eleftheria Zeggini, Antigone S Dimas","doi":"10.1038/s44324-025-00057-2","DOIUrl":"10.1038/s44324-025-00057-2","url":null,"abstract":"<p><p>Dietary interventions constitute powerful approaches for disease prevention and treatment. However, the molecular mechanisms through which diet affects health remain underexplored in humans. Here, we compare plasma metabolomic and proteomic profiles between dietary states for a unique group of individuals who alternate between omnivory and restriction of animal products for religious reasons. We find that short-term restriction drives reductions in levels of lipid classes and of branched-chain amino acids, not detected in a control group of individuals, and results in metabolic profiles associated with decreased risk for all-cause mortality. We show that 23% of proteins whose levels are affected by dietary restriction are druggable targets and reveal that pro-longevity hormone FGF21 and seven additional proteins (FOLR2, SUMF2, HAVCR1, PLA2G1B, OXT, SPP1, HPGDS) display the greatest magnitude of change. Through Mendelian randomization we demonstrate potentially causal effects of FGF21 and HAVCR1 on risk for type 2 diabetes, of HPGDS on BMI, and of OXT on risk for lacunar stroke. Collectively, we find that restriction-associated reprogramming improves metabolic health and emphasise high-value targets for pharmacological intervention.</p>","PeriodicalId":501710,"journal":{"name":"npj Metabolic Health and Disease","volume":"3 1","pages":"14"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11981922/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144036846","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
AMPK phosphosite profiling by label-free mass spectrometry reveals a multitude of mTORC1-regulated substrates. 通过无标记质谱分析AMPK磷酸谱揭示了多种mtorc1调节的底物。
npj Metabolic Health and Disease Pub Date : 2025-01-01 Epub Date: 2025-03-04 DOI: 10.1038/s44324-025-00052-7
William J Smiles, Ashley J Ovens, Dingyi Yu, Naomi X Y Ling, Andrea C Poblete Goycoolea, Kaitlin R Morrison, Emmanuel O Murphy, Astrid Glaser, Sophie F Monks O'Byrne, Scott Taylor, Alistair M Chalk, Carl R Walkley, Luke M McAloon, John W Scott, Bruce E Kemp, Ashfaqul Hoque, Christopher G Langendorf, Janni Petersen, Sandra Galic, Jonathan S Oakhill
{"title":"AMPK phosphosite profiling by label-free mass spectrometry reveals a multitude of mTORC1-regulated substrates.","authors":"William J Smiles, Ashley J Ovens, Dingyi Yu, Naomi X Y Ling, Andrea C Poblete Goycoolea, Kaitlin R Morrison, Emmanuel O Murphy, Astrid Glaser, Sophie F Monks O'Byrne, Scott Taylor, Alistair M Chalk, Carl R Walkley, Luke M McAloon, John W Scott, Bruce E Kemp, Ashfaqul Hoque, Christopher G Langendorf, Janni Petersen, Sandra Galic, Jonathan S Oakhill","doi":"10.1038/s44324-025-00052-7","DOIUrl":"10.1038/s44324-025-00052-7","url":null,"abstract":"<p><p>The nutrient-sensitive protein kinases AMPK and mTORC1 form a fundamental negative feedback loop that governs cell growth and proliferation. mTORC1 phosphorylates α2-S345 in the AMPK αβγ heterotrimer to suppress its activity and promote cell proliferation under nutrient stress conditions. Whether AMPK contains other functional mTORC1 substrates is unknown. Using mass spectrometry, we generated precise stoichiometry profiles of phosphorylation sites across all twelve AMPK complexes expressed in proliferating human cells and identified seven sites displaying sensitivity to pharmacological mTORC1 inhibition. These included the abundantly phosphorylated residues β1-S182 and β2-S184, which were confirmed as mTORC1 substrates on purified AMPK, and four residues in the unique γ2 N-terminal extension. β-S182/184 phosphorylation was elevated in α1-containing complexes relative to α2, an effect attributed to the α-subunit serine/threonine-rich loop. Mutation of β1-S182 to non-phosphorylatable Ala had no effect on basal and ligand-stimulated AMPK activity; however, β2-S184A mutation increased nuclear AMPK activity, enhanced cell proliferation under nutrient stress and altered expression of genes implicated in glucose metabolism and Akt signalling. Our results indicate that mTORC1 directly or indirectly phosphorylates multiple AMPK residues that may contribute to metabolic rewiring in cancerous cells.</p>","PeriodicalId":501710,"journal":{"name":"npj Metabolic Health and Disease","volume":"3 1","pages":"8"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11879883/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143575037","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Reversal of metformin's anti-proliferative effect in fission yeast efr3 and dnm1 (DRP1) mutants with elongated mitochondria. 逆转二甲双胍在线粒体拉长的裂殖酵母efr3和dnm1(DRP1)突变体中的抗增殖作用。
npj Metabolic Health and Disease Pub Date : 2025-01-01 Epub Date: 2025-02-21 DOI: 10.1038/s44324-024-00048-9
Ari Gillespie, Anne-Sophie Mehdorn, Tiffany Q Lim, Tingting Wang, Bridget A Mooney, Ashley J Ovens, Ayla Orang, Jonathan S Oakhill, Michael Z Michael, Janni Petersen
{"title":"Reversal of metformin's anti-proliferative effect in fission yeast <i>efr3</i> and <i>dnm1</i> (DRP1) mutants with elongated mitochondria.","authors":"Ari Gillespie, Anne-Sophie Mehdorn, Tiffany Q Lim, Tingting Wang, Bridget A Mooney, Ashley J Ovens, Ayla Orang, Jonathan S Oakhill, Michael Z Michael, Janni Petersen","doi":"10.1038/s44324-024-00048-9","DOIUrl":"10.1038/s44324-024-00048-9","url":null,"abstract":"<p><p>Metformin is a well-tolerated drug frequently prescribed for managing type 2 diabetes. Extended metformin use has been linked to a significant decrease in cancer incidence across both diabetic and non-diabetic populations. Here we investigate the anti-proliferative effects of metformin on fission yeast <i>S. pombe</i>. Our findings demonstrate that metformin's inhibitory impact on cell proliferation is effective in the absence of AMP-activated protein kinase (AMPK). Using an unbiased genetic screen we identified the plasma membrane signalling scaffold Efr3, critical for phosphatidylinositol signalling and the generation of PI4Ps, as a key determinant of resistance to the anti-proliferative effect of metformin. Deletion of <i>efr3</i> resulted in both AMPK-dependent and AMPK-independent resistance to metformin. We show that Efr3 does not influence cell proliferation by controlling Ras1 activity or its cellular localization in yeast. We observe that <i>dnm1</i> (DRP1) mutants with elongated mitochondria are also resistant to the anti-proliferative effect of metformin and that metformin treatment promotes mitochondrial fusion. Metabolic measurements after prolonged metformin exposure demonstrated a reduction in respiration in both wild type and the <i>efr3</i> deletion, however, that reduction is less pronounced in the <i>efr3</i> deletion, which also contained elongated mitochondria. It is likely that mitochondrial fusion enhances yeast fitness in response to metformin exposure. Together we provide a new perspective on the cellular response to metformin.</p>","PeriodicalId":501710,"journal":{"name":"npj Metabolic Health and Disease","volume":"3 1","pages":"5"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11845315/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143485196","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Reshaping lipid metabolism with long-term alternate day feeding in type 2 diabetes mice. 长期隔日喂养重塑2型糖尿病小鼠脂质代谢。
npj Metabolic Health and Disease Pub Date : 2025-01-01 Epub Date: 2025-02-03 DOI: 10.1038/s44324-024-00039-w
Eleni Beli, Yuanqing Yan, Leni Moldovan, Todd A Lydic, Preethi Krishman, Sarah A Tersey, Yaqian Duan, Tatiana E Salazar, James M Dominguez, Dung V Nguyen, Abigail Cox, Sergio Li Calzi, Craig Beam, Raghavendra G Mirmira, Carmella Evans-Molina, Julia V Busik, Maria B Grant
{"title":"Reshaping lipid metabolism with long-term alternate day feeding in type 2 diabetes mice.","authors":"Eleni Beli, Yuanqing Yan, Leni Moldovan, Todd A Lydic, Preethi Krishman, Sarah A Tersey, Yaqian Duan, Tatiana E Salazar, James M Dominguez, Dung V Nguyen, Abigail Cox, Sergio Li Calzi, Craig Beam, Raghavendra G Mirmira, Carmella Evans-Molina, Julia V Busik, Maria B Grant","doi":"10.1038/s44324-024-00039-w","DOIUrl":"10.1038/s44324-024-00039-w","url":null,"abstract":"<p><p>Strategies to improve metabolic health include calorie restriction, time restricted eating and fasting several days per week or month. These approaches have demonstrated benefits for individuals experiencing obesity, metabolic syndrome, and prediabetes. However, their impact on established diabetes remains incompletely studied. The chronicity of type 2 diabetes (T2D) requires that interventions must be undertaken for extended periods of time, typically the entire lifetime of the individual. In this study, we examined the impact of intermittent fasting (IF), with an every-other-day protocol for a duration of 6 months in a murine model of T2D, the db/db (D) mouse on metabolism and liver steatosis. We compared D-IF mice with diabetic ad-libitum (AL; D-AL), control-IF (C-IF) and control-AL (C-AL) cohorts. We demonstrated using lipidomic, microbiome, metabolomic and liver transcriptomic studies that chronic IF improved carbohydrate utilization and glucose homeostasis without weight loss and reduced white adipose tissue inflammation and significantly impacted lipid metabolism in the liver. Microbiome studies and predicted functional analysis of gut microbiota showed that IF increased beneficial bacteria involved in sphingolipid (SL) metabolism. The metabolomic studies showed that oxidation of lipid species and ceramide levels were reduced in D-IF compared to D-AL. The liver lipidomic analysis and liver microarray confirmed a reduction in overall lipid content in D-IF mice compared to D-AL mice, especially in the feeding state as well as an overall reduction in oxidized lipids and ceramides. These studies support that long-term IF can improve glucose homeostasis and dramatically altered lipid metabolism in the absence of weight loss.</p>","PeriodicalId":501710,"journal":{"name":"npj Metabolic Health and Disease","volume":"3 1","pages":"3"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11790504/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143257770","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Incretin triple agonist retatrutide (LY3437943) alleviates obesity-associated cancer progression. 肠促胰岛素三重激动剂利特鲁肽(LY3437943)缓解肥胖相关的癌症进展。
npj Metabolic Health and Disease Pub Date : 2025-01-01 Epub Date: 2025-03-14 DOI: 10.1038/s44324-025-00054-5
Sandesh J Marathe, Emily W Grey, Margaret S Bohm, Sydney C Joseph, Arvind V Ramesh, Matthew A Cottam, Kamran Idrees, Kathryn E Wellen, Alyssa H Hasty, Jeffrey C Rathmell, Liza Makowski
{"title":"Incretin triple agonist retatrutide (LY3437943) alleviates obesity-associated cancer progression.","authors":"Sandesh J Marathe, Emily W Grey, Margaret S Bohm, Sydney C Joseph, Arvind V Ramesh, Matthew A Cottam, Kamran Idrees, Kathryn E Wellen, Alyssa H Hasty, Jeffrey C Rathmell, Liza Makowski","doi":"10.1038/s44324-025-00054-5","DOIUrl":"10.1038/s44324-025-00054-5","url":null,"abstract":"<p><p>Medical therapeutics for weight loss are changing the landscape of obesity but impacts on obesity-associated cancer remain unclear. We report that in pre-clinical models with significant retatrutide (RETA, LY3437943)-induced weight loss, pancreatic cancer engraftment was reduced, tumor onset was delayed, and progression was attenuated resulting in a 14-fold reduction in tumor volume compared to only 4-fold reduction in single agonist semaglutide-treated mice. Despite weight re-gain after RETA withdrawal, the anti-tumor benefits of RETA persisted. Remarkably, RETA-induced protection extends to a lung cancer model with 50% reduced tumor engraftment, significantly delayed tumor onset, and mitigated tumor progression, with a 17-fold reduction in tumor volume compared to controls. RETA induced immune reprogramming systemically and in the tumor microenvironment with durable anti-tumor immunity evidenced by elevated circulating IL-6, increased antigen presenting cells, reduced immunosuppressive cells, and activation of pro-inflammatory pathways. In sum, our findings suggest that patients with RETA-mediated weight loss may also benefit from reduced cancer risk and improved outcomes.</p>","PeriodicalId":501710,"journal":{"name":"npj Metabolic Health and Disease","volume":"3 1","pages":"10"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11908972/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143653109","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Characterization and treatment monitoring of ureagenesis disorders using stable isotopes. 利用稳定同位素对尿源性疾病进行表征和治疗监测。
npj Metabolic Health and Disease Pub Date : 2025-01-01 Epub Date: 2025-05-06 DOI: 10.1038/s44324-025-00051-8
Gabriella Allegri, Martin Poms, Nadia Zürcher, Véronique Rüfenacht, Nicole Rimann, Déborah Mathis, Beat Thöny, Matthias Gautschi, Ralf A Husain, Daniela Karall, Karolina Orchel-Szastak, Francesco Porta, Dominique Roland, Barbara Siri, Carlo Dionisi-Vici, René Santer, Johannes Häberle
{"title":"Characterization and treatment monitoring of ureagenesis disorders using stable isotopes.","authors":"Gabriella Allegri, Martin Poms, Nadia Zürcher, Véronique Rüfenacht, Nicole Rimann, Déborah Mathis, Beat Thöny, Matthias Gautschi, Ralf A Husain, Daniela Karall, Karolina Orchel-Szastak, Francesco Porta, Dominique Roland, Barbara Siri, Carlo Dionisi-Vici, René Santer, Johannes Häberle","doi":"10.1038/s44324-025-00051-8","DOIUrl":"10.1038/s44324-025-00051-8","url":null,"abstract":"<p><p>Urea cycle disorders (UCDs) are a group of rare conditions, possibly life-threatening and without definitive cure besides liver transplantation. Traditional biochemical analyses/biomarkers cannot reliably determine changes in the UC-function from baseline to post-intervention. We describe a UHPLC-HRMS method to assess ureagenesis in plasma and dried blood spots for [<sup>15</sup>N]urea and [<sup>15</sup>N]amino acids, using [<sup>15</sup>N]ammonium chloride as tracer. [<sup>15</sup>N]enrichment of urea and amino acids was studied in controls (<i>n</i> = 22) and patients (<i>n</i> = 59), the latter showing characteristic ureagenesis variations according to their underlying metabolic defect. Follow-up of therapies was successful, as we observed restoration of [<sup>15</sup>N]urea production and lowering of [<sup>15</sup>N]glutamine. There were no adverse events, and only minimal amounts of tracer and samples required with a short sample preparation time and analysis. Thus, the method proved to be safe and efficient to monitor UCD patients of variable severity pre- and post-therapy, being suitable as physiological endpoint for development of therapies.</p>","PeriodicalId":501710,"journal":{"name":"npj Metabolic Health and Disease","volume":"3 1","pages":"19"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12055570/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144039698","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Clinical associations and potential cellular mechanisms linking G6PD deficiency and atherosclerotic cardiovascular disease. G6PD缺乏与动脉粥样硬化性心血管疾病的临床关联和潜在细胞机制
npj Metabolic Health and Disease Pub Date : 2025-01-01 Epub Date: 2025-04-24 DOI: 10.1038/s44324-025-00061-6
Patrick H Andrews, James C Zimring, Coleen A McNamara
{"title":"Clinical associations and potential cellular mechanisms linking G6PD deficiency and atherosclerotic cardiovascular disease.","authors":"Patrick H Andrews, James C Zimring, Coleen A McNamara","doi":"10.1038/s44324-025-00061-6","DOIUrl":"10.1038/s44324-025-00061-6","url":null,"abstract":"<p><p>Glucose 6-phosphate dehydrogenase deficiency (G6PD-d) is the most common enzymopathy in the world, occurring in 5-8% of the global population (half a billion people). Recent epidemiological evidence suggests that G6PD-d may be associated with increased cardiovascular disease (CVD). Atherosclerosis is the dominant cause of CVD, including myocardial infarction, heart failure, stroke, and peripheral artery disease. Atherosclerosis, in turn, is a chronic inflammatory disease, fueled by oxidized lipids and influenced by various immune and nonimmune cells including vascular endothelial and smooth muscle cells, monocytes and macrophages, T cells, B cells, and red blood cells. Here, we review the existing epidemiological evidence supporting a role for G6PD-d in CVD in humans and explore the data on potential cellular mechanisms by which G6PD-d may exacerbate atherosclerosis.</p>","PeriodicalId":501710,"journal":{"name":"npj Metabolic Health and Disease","volume":"3 1","pages":"16"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12021654/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144002902","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Potential bidirectional communication between the liver and the central circadian clock in MASLD. 在MASLD中肝脏和中央生物钟之间潜在的双向交流。
npj Metabolic Health and Disease Pub Date : 2025-01-01 Epub Date: 2025-04-09 DOI: 10.1038/s44324-025-00058-1
Frédéric Gachon, Elisabetta Bugianesi, Gabriele Castelnuovo, Henrik Oster, Julie S Pendergast, Sara Montagnese
{"title":"Potential bidirectional communication between the liver and the central circadian clock in MASLD.","authors":"Frédéric Gachon, Elisabetta Bugianesi, Gabriele Castelnuovo, Henrik Oster, Julie S Pendergast, Sara Montagnese","doi":"10.1038/s44324-025-00058-1","DOIUrl":"10.1038/s44324-025-00058-1","url":null,"abstract":"<p><p>Most aspects of physiology and behaviour fluctuate every 24 h in mammals. These circadian rhythms are orchestrated by an autonomous central clock located in the suprachiasmatic nuclei that coordinates the timing of cellular clocks in tissues throughout the body. The critical role of this circadian system is emphasized by increasing evidence associating disruption of circadian rhythms with diverse pathologies. Accordingly, mounting evidence suggests a bidirectional relationship where disruption of rhythms by circadian misalignment may contribute to liver diseases while liver diseases alter the central clock and circadian rhythms in other tissues. Therefore, liver pathophysiology may broadly impact the circadian system and may provide a mechanistic framework for understanding and targeting metabolic diseases and adjust metabolic setpoints.</p>","PeriodicalId":501710,"journal":{"name":"npj Metabolic Health and Disease","volume":"3 1","pages":"15"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11981938/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144057201","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Intermittent fasting as a treatment for obesity in young people: a scoping review 间歇性禁食作为治疗年轻人肥胖的一种方法:范围综述
npj Metabolic Health and Disease Pub Date : 2024-12-30 DOI: 10.1038/s44324-024-00041-2
Jomanah Bakhsh, Sarah-Jeanne Salvy, Alaina P. Vidmar
{"title":"Intermittent fasting as a treatment for obesity in young people: a scoping review","authors":"Jomanah Bakhsh,&nbsp;Sarah-Jeanne Salvy,&nbsp;Alaina P. Vidmar","doi":"10.1038/s44324-024-00041-2","DOIUrl":"10.1038/s44324-024-00041-2","url":null,"abstract":"Intermittent fasting focuses on the timing of eating rather than diet quality or energy intake, with evidence supporting its effects on weight loss and improvements in cardiometabolic outcomes in adults with obesity. However, there is limited evidence for its feasibility and efficacy in young people. To address this, a scoping review was conducted to examine intermittent fasting regimens in individuals aged 10 to 25 for the treatment of obesity focusing on methodology, intervention parameters, outcomes, adherence, feasibility, and efficacy. Due to the paucity of evidence in this age group, to adequately assess feasibility and adherence, all published studies of intermittent fasting in this age category, regardless of weight status and treatment intention, were included in the review. The review included 34 studies (28 interventional studies and 6 observational studies) with 893 participants aged 12 to 25. Interventions varied with 9 studies in cohorts with obesity utilizing intermittent fasting as an obesity treatment. Thirteen studies utilized 8-h time-restricted eating. Primary outcomes included cardiometabolic risk factors (7/28), anthropometric measurements (7/28), body composition (5/28), muscular performance (4/28), feasibility (1/28), and others (4/28). All 9 studies conducted in young people with obesity reported some degree of weight loss, although the comparator groups varied significantly. This review underscores the various utilizations of intermittent fasting in this age group and highlights its potential in treating obesity. However, the findings emphasize the need for rigorous studies with standardized frameworks for feasibility to ensure comparability and determine intermittent fasting’s practicality in this age group depending on the treatment outcome of interest.","PeriodicalId":501710,"journal":{"name":"npj Metabolic Health and Disease","volume":" ","pages":"1-19"},"PeriodicalIF":0.0,"publicationDate":"2024-12-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.nature.com/articles/s44324-024-00041-2.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142906112","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The effect of high-sugar feeding on rodent metabolic phenotype: a systematic review and meta-analysis 高糖摄食对啮齿动物代谢表型的影响:系统回顾和荟萃分析
npj Metabolic Health and Disease Pub Date : 2024-12-30 DOI: 10.1038/s44324-024-00043-0
Sophie Lucic Fisher, G. Jean Campbell, Alistair Senior, Kim Bell-Anderson
{"title":"The effect of high-sugar feeding on rodent metabolic phenotype: a systematic review and meta-analysis","authors":"Sophie Lucic Fisher,&nbsp;G. Jean Campbell,&nbsp;Alistair Senior,&nbsp;Kim Bell-Anderson","doi":"10.1038/s44324-024-00043-0","DOIUrl":"10.1038/s44324-024-00043-0","url":null,"abstract":"Dietary sugar consumption has been linked to increased cardiometabolic disease risk, although it is unclear if this is independent of increases in body weight and adiposity. Additionally, many preclinical animal studies provide liquid sugar which more readily leads to excess consumption and weight gain, confounding any outcomes driven by high-sugar intake alone. To gain clarity on this, we conducted a systematic review and meta-analysis exclusively investigating the effect of isocaloric high-sugar, low-fat solid diet formulations containing fructose or sucrose, on cardiometabolic health in rodents. Overall, we found strong evidence that fructose and sucrose have effects on metabolic health, independent of body weight gain. High-sugar feeding, with fructose in particular, altered liver phenotype; ALT (d = 1.08; 0.66, 1.5), triglyceride content (d = 0.52; 0.25, 0.78), cholesterol (d = 0.59; 0.16, 1.03) and liver mass (d = 0.93; 0.37, 1.48), and glucose tolerance; fasting glucose (d = 0.60; 0.18, 1.01) and fasting insulin (d = 0.42; 0.07, 0.77) but not body weight or energy intake. Our review also highlights the lack of data reported on adiposity and in female rodents. This is the first meta-analysis to synthesise all current rodent solid diet high-sugar studies, while adjusting them for confounders (fat content, time spent on diet and age started on diet) and suggests that high-sugar dietary intake and composition alters metabolic health of mice regardless of weight gain.","PeriodicalId":501710,"journal":{"name":"npj Metabolic Health and Disease","volume":" ","pages":"1-13"},"PeriodicalIF":0.0,"publicationDate":"2024-12-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.nature.com/articles/s44324-024-00043-0.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142906125","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信